Skip to main content
. 2022 Nov 11;75(2):242–252. doi: 10.1002/art.42391

Figure 2.

Figure 2

Adjusted mean percentage change from baseline (BL) over 48‐week follow‐up in levels of anti–double‐stranded DNA (anti‐dsDNA) antibodies in patients with detectable anti‐dsDNA at baseline (A), C3 complement in patients with C3 <0.9 gm/liter at baseline (B), and C4 complement in patients with C4 <0.1 gm/liter at baseline (C) for patient groups receiving deucravacitinib 3 mg twice daily (BID), deucravacitinib 6 mg twice daily, deucravacitinib 12 mg once daily (QD), or placebo for treatment of systemic lupus erythematosus. In A–C, vertical bars indicate 95% confidence intervals (95% CIs). Imputation was done using a mixed‐effects model. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.42391/abstract.